PF-05089771
Sponsors
Pfizer, Medical University of Vienna
Conditions
HealthyInherited ErythromelalgiaPainPostoperative Dental Pain
Early Phase 1
Phase 1
To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity
CompletedNCT01165736
Start: 2010-07-31End: 2010-08-31Updated: 2010-08-24
A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers
CompletedNCT01259882
Start: 2010-12-31End: 2011-09-30Updated: 2012-02-02
The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.
CompletedNCT01365637
Start: 2011-06-30End: 2011-09-30Updated: 2011-10-06
A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee
CompletedNCT01529671
Start: 2012-01-31End: 2012-10-31Updated: 2012-12-12
A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State
CompletedNCT01563497
Start: 2012-02-29End: 2012-02-29Updated: 2012-03-27
A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State
CompletedNCT01690351
Start: 2012-09-30End: 2012-09-30Updated: 2012-12-12
Safety And Tolerability Study Of BID Titration Scheme With PF-05089771
CompletedNCT01772264
Start: 2013-01-31End: 2013-04-30Updated: 2013-05-10
Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion
CompletedNCT01854996
Start: 2013-05-31End: 2013-06-30Updated: 2013-06-25
Phase 2
Efficacy Of PF-05089771 In Treating Postoperative Dental Pain
CompletedNCT01529346
Start: 2011-12-12End: 2012-06-25Updated: 2018-06-01
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
CompletedNCT01769274
Start: 2012-10-22End: 2013-07-12Updated: 2019-11-19